RxDoctor Payments Data

Narender Thatikonda, MD

Internal Medicine · Ovid, MINPI 1023215886

Payments from drug & device makers

$1,100in general payments, 2019–2025

Across 62 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$177
  • Otsuka America Pharmaceutical, Inc.$129
  • Novo Nordisk$123
  • Amgen$122
  • GSK$99
  • AstraZeneca$80
  • plus $369 from 12 others

What the payments were for

  • Food & beverage$1,100100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,100 in reported general payments places this provider in the 75th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$36,961
Medicare patients
95
Services billed
448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$69,904
JardianceEmpagliflozin53$66,159
JanuviaSitagliptin Phosphate33$43,775
OzempicSemaglutide19$36,496
XareltoRivaroxaban25$26,320
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$25,150
FarxigaDapagliflozin Propanediol13$15,882
RexultiBrexpiprazole11$15,323
Combivent RespimatIpratropium/Albuterol Sulfate17$13,720
EntrestoSacubitril/Valsartan16$11,953
Breo ElliptaFluticasone/Vilanterol14$8,838
LinzessLinaclotide15$7,604
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$5,985
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$5,610
Atorvastatin Calcium323$3,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo, Paxlovid$41$74,679107 claims
Novo NordiskOzempic$123$36,49619 claims
GSKTrelegy Ellipta, Breo Ellipta$99$33,98844 claims
AstraZenecaFarxiga$80$15,88213 claims
Otsuka America Pharmaceutical, Inc.Rexulti$129$15,32311 claims
AbbVieLinzess$177$7,60415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Ovid

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →